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ABSTRACT 
Transcriptional co-activators and co-repressors are emerging as physiological 
integrators of energy metabolism and other biological processes. Tissues and organs 
need to adapt to different critical physiological process as energetic metabolism, 
apoptosis or ROS signaling. The correct number of structural and functionally 
differentiated mitochondria mediates all these processes. In consequence, mitochondrial 
biogenesis must be strictly regulated, a process that implies the coordinated regulation 
of nuclear and mitochondrial genome gene expression. In mammals, PGC-1 co-
activators are essential to integrate the response of a network of specific transcription 
factors involved in mitochondria biogenesis. Here, we focus on the role of the PGC-1 
co-activator family. These proteins are key players in the control of organ-specific 
biologic responses to the physiologic environment. Emphasis will be given to tissue-
specific regulatory features relevant to muscle. Our knowledge of the PGC-1 family in 
vertebrates has augmented, but even now the molecular networks on which these co-
regulators are implicated, the PGC-1 response to the external signal and how molecular 
pathways are functionally integrated to activate gene expression programs are mostly 
unknown. In this sense, the studies of the function of the unique member of Drosophila 
identified and the comparative analysis between flies and mammals will help in our 
understanding of the integrative signals mediated by PGC-1 co-activator protein family. 
Here we show that Drosophila PGC-1, Spargel/dPGC-1 may play also a crucial role in 
mitochondrial biogenesis. Homozygous dPGC-1 null mutants are not fertile and present 
strong muscle phenotype. These mutants are unable to fly and electron microscopy 
studies of flight muscles from these animals show clear fiber degeneration. Very 
interestingly, we have also found a strong reduction of both mitochondrial electron 
density and size. Fly and mammals comparative analysis will be presented. 
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INTRODUCTION 
During development as animal grow, cells need to adapt to different physiological 
process as energetic metabolism, apoptosis or ROS signaling. In these processes, 
mitochondria have critical anabolic and catabolic functions in metabolizing nutrients 
and in adapting their cellular physiology. The correct number of structural and 
functionally differentiated mitochondria mediates all these actions. Therefore, 
mitochondrial biogenesis must be strictly regulated and nuclear and mitochondrial 
genome’s gene expression must be coordinated. 
The last two decades have witnessed a tremendous expansion in our knowledge of the 
mechanisms employed by eukaryotic cells to control gene activity. Transcriptional co-
activators and co-repressors are emerging as physiological integrators of energy 
metabolism and other biological events [1, 2]. A common theme of these co-activator 
regulatory networks it that, by co-activating multiple transcription factor targets they are 
able to coordinate diverse biological processes that constitute biological responses [3, 
4]. 
To learn about mitochondrial biogenesis, most studies focused on individual tissues that 
show an enormous increase in mitochondrial activity and mass in response to external 
stimuli, for example, during brown adipose tissue, muscle or perinatal heart maturation. 
These studies led to identification and characterization of the PGC-1 family of 
transcriptional co-activators that are potent inducers of mitochondrial biogenesis [5, 6]. 
A critical aspect of the PGC-1 co-activators is that they are highly versatile and have the 
ability to interact with many different transcription factors. In fact, in vertebrates, the 
PGC-1 proteins are inducible transcriptional co-activators orchestrating control of 
cellular energy metabolism [4, 7]. Less is known about the role of the unique member of 
the PGC-1 family present in the Drosophila model system, recently identify by our 
group and others [8]. 
Although our knowledge of the PGC-1α  in vertebrates has increased substantially, not 
all the molecular pathways in the biological processes on which these co-regulators are 
involved are known. Moreover, it is unclear how PGC-1α  responds to the different 
external stimuli and how molecular pathways are functionally integrated in different 
gene expression programs.   
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In flies, the homologue of PGC-1a, Spargel/dPGC-1, seems to play a critical role in 
mitochondrial biogenesis in fat body and muscle, coordinating mitochondrial activity 
and insulin signaling [8]. Drosophila is an excellent system to profound the knowledge 
of mitochondria and muscle for three reasons: 1) Its powerful genetics combined with a 
wealth of available cell and molecular biology techniques; 2) Genetic pathways that 
guide basic biological processes, in Drosophila and in vertebrates, have remained 
largely intact throughout evolution. This conservation enables rapid analysis of these 
processes in vertebrates and 3) Habitually in flies, one single member represents a 
functional gene family in vertebrates facilitating functional studies. 
PGC-1 family members in vertebrates drive mitochondrial biogenesis through co-
activation of nuclear transcription factors. The majority of these factors are conserved in 
flies. Thus, the transcription factors, Erect wing, homolog of NRF1, plays a critical role 
in neural and muscle development; Delg, homolog of NRF2, is required during 
oogenesis; NRGF, binds NRG sequences (nuclear regulatory gene elements) localized 
in mitochondrial gene promoters and DREF is involved in DNA replication and cell 
cycle control are conserved [8, 9]. At the moment, no Drosophila transcriptional co-
regulators have been characterized as physiological integrators of energy metabolism 
and other biological processes. We think flies will help, in the near future, to unravel 
some of the open and common questions about the exact role of PGC-1 in the 
integration and coordination of the different regulatory networks in which this co-
activator is implicated.  
This review will focus on the role of the PGC-1 co-activator family. These proteins are 
key players in the control of organ-specific biologic responses to the physiologic milieu. 
Emphasis will be given to tissue-specific regulatory features relevant to fat body and 
muscle. Our knowledge of the PGC-1family in vertebrates has augmented, but even 
now the molecular networks on which these co-regulators are implicated are largely 
known. At the moment, the complete mechanisms of how PGC-1 responds to the 
external signals and how molecular pathways are functionally integrated to activate 
gene expression programs are unknown. In this sense, the studies of the function of the 
unique member of Drosophila identified [8], and the comparative analysis between flies 
and mammals will help in our understanding of the integrative signals mediated by 
PGC-1 co-activator protein family. Fly and mammals comparative analysis will be 
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presented. 
RESULTS AND DISCUSSION 
Molecular Conservation of PGC-1 co-activator family genes 
In silico analysis has shown that PGC-1 family of co-activators is conserved in many 
chordate species, including primates, rodents, ruminants, birds, amphibians and fishes 
[5]. In vertebrates, three members compose this family; the first identified was PGC-
1α , characterized as a PPARγ -interacting protein and isolated from brown fat [10]. 
PGC-1α  has two structural homologues, PGC-1β  which shares an extensive sequence 
homology with PGC-1α  [11, 12], and PRC-related co-activator (PRC) with more 
limited overall sequence similarity with PGC1α and PGC1β but sharing the key 
structural features that define the family [13]. Detailed protein analysis reveals different 
conserved functional domains (Figure 1). In the N-terminal acidic region, there is a 
transcription activation domain that contains one nuclear hormone co-activator 
signature motif (LXXLL) in PGC-1α and two of these motifs in PGC-1β that are crucial 
for co-activation through certain nuclear receptors. In the central region of the PGC-1 
proteins, a regulatory domain, mainly involved in co-activation through binding to 
different mitochondrial transcriptional factors, exists. In the C-terminal region a 
Ser/Arg-rich motif is situated close to a RNA binding domain [5]. 
In Drosophila melanogaster, a single homologue, annotated CG9809 and located in 
chromosome 3R, has been identified [14]. This gene encodes a predicted protein of 
1.088 amino acids and contains a RNA binding motif in the C-terminal region that 
exhibits approximately 60% of homology with the same region in mammalian PGC-1 α  
and β  genes. Moreover, the Drosophila protein includes an acidic NH2-terminal 
domain and an arginine-serine-rich domain common with its mammalian homologue 
genes [14, 15] (Figure 1). Although the canonical LXXLL nuclear receptor binding 
motif is not present, dPGC-1 contains a conserved variant of this motif FXXLL in the 
C-terminal region which has been demonstrated to be involved in nuclear receptor 
binding [16]. Thus, Drosophila and vertebrate PGC-1α proteins contain the functional 
domain involved in nuclear receptor binding.  
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FIGURE 1: Molecular conservation of mammalian and Drosophila PGC-1 co-activator family. In 
the upper part the sequence homology of PRC, PGC-1β  and PGC-1α  proteins is shown. Color boxes 
represent protein domains: activation domain (red), Arg/Ser rich domain (orange) and RNA binding 
domain (blue). Black lines denote LXXL motifs (nuclear receptor binding sites). In the lower part, PGC-
1α  and PGC-1 of Drosophila (dPGC-1) sequence homology is presented. Note the high percentage of 
homology in RNA binding domain, RRM domain. No LXXL-like motifs have been identified in 
Drosophila. Also note that sequence F(D/E)XLL is common to the carboxy-terminal domains of all PGC-
1 family members. 
 
PGC1 proteins function as inducible transcriptional co-activators: molecular 
mechanism 
The discovery of the first transcriptional co-activators and co-repressors for nuclear 
hormone receptors and other transcription factors initiated a novel concept centered 
around the control of specific genetic programs coordinated at the level of these proteins 
[10]. Co-activators act interacting with various transcription factors, allowing for the 
coordinated expression of gene sets in response to specific signals. Another important 
and interesting implication of co-activators is the possibility to activate gene expression 
in very specific contexts. The members of the inducible PGC-1 transcriptional co-
activator family posses a common function in mitochondrial physiology in addition to 
control other specific programs. In the cells, PGC-1 gene expression is modified in 
response to a variety of extracellular stimuli including temperature, energy deprivation 
and availability of nutrients and grows factors [6, 17, 18]. However, these co-activators 
exhibit differential specificities for transcription factors utilization, which in turn 
modulates the physiological response orchestrated by each co-activator [7]. 
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The molecular mechanisms through which PGC-1α  activates gene expression are 
poorly understood. These co-activators form part of protein complexes whose concrete 
protein identity and enzymatic activities are not completely known. Molecular studies, 
mostly performed in cell cultures, indicate that PGC-1α  and PGC-1β  function through 
recruiting chromatin-remodeling complexes that include those involved in histone 
modification and nucleosome remodeling (reviewed in [18]). PGC-1α  activates 
transcription by physical interaction with p300 histone acetyltransferase domain 
containing proteins as P300, CBP, SRC-1 and GCN5 as well as the mediator protein 
complex, which is thought to recruit RNA polymerase II [19-22]. In the liver, where it 
participates in the regulation of lipid metabolism, PGC-1α  interacts with BRG1/BRM-
associated factor (BAF60a), a subunit of SW1/SNF nucleosome remodeling complex. 
This interaction is required for the transcriptional function of PPARα  (peroxisome 
proliferator-activated receptor) and may be implicated in transcriptional function of 
other nuclear hormone receptors [23, 24]. The recruitment of these histone acetyl-
transferase complexes containing PGC-1α to the proximity of the target-genes increases 
histone acetylation, one of the first steps in transcriptional activation.  
Another important aspect to understand is how these complexes may be spatially and 
temporally assembled with PGC-1α to modulate and activate gene expression. Not 
much is known about how these events occur, but modulation of transcription is 
achieved through acetylation /deacetylation of PGC-1α itself.  PGC-1 α has been found 
in association with two additional different transcriptional complexes, the GCN5 and 
TIP60 acetyl transferase complexes. The acetyl transferase GCN5 directly acetylates 
PGC-1α  at multiple lysine residues and the acetylated protein negatively regulates its 
transcriptional activation function, at least in part through nuclear sub-localization [21]. 
The opposite role is played by lysine de-acetylation of PGC-1 by SIRT1 which 
increases its function in response to cellular nutrients [25-28].  
The model described above is perhaps simplistic and does not take into account other 
additional PGC-1 post-translational modifications such as phosphorylation and 
methylation whose precise functions are still unknown. Thus, PGC-1α  phosphorylation 
by the p38 MAPK and AMP kinase (AMPK) has been described [29-31]. Also, 
methylation [32] and the novel O-linked β-N-acetylglucosamine (O-GlcNAc) 
modifications on PGC-1α  have been shown. The last, modulating the activity of FoxO 
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transcription factors in liver culture cells [33]. On the other hand, the RNA-binding 
domain of PGC-1α  has been implicated in processing many mRNAs whose 
transcription it initiates [34].  
PCG-1α, PGC-1β and PRC act as transcriptional co-activators and function through 
direct physical interaction with transcription factors directly bound to DNA promoter 
regions. Thus, through their N-terminal region they interact with different hormone 
nuclear receptors including PPARs, HNF4α, GR and ERRα  while through their central 
region bind transcription factors implicated in the activation of mitochondrial 
biogenesis and respiratory function, such as NRF1, NRF2, TFAM, TBPs and MEF2C 
[5, 7]. In addition, they interact with the RNA-processing C-terminal region with other 
transcriptional factor group such as FoxO and YY1 involved in other pathways [35]. As 
mentioned in the Introduction, the ability of PGC-1α to interact with different 
transcription factors allows for the coordinated expression of gene sets in response to 
specific signals (Figure 2).  
In this context, in vertebrates, it has been described that NRF-1 transcription factor 
regulates the expression of many genes involved in mitochondrial regulatory including 
the majority of nuclear genes that encode subunits of the five respiratory complexes as 
well as the expression of Tfam [36], and the two TFB genes [37], the main regulators of 
mitochondrial transcription. Both NRF-1 and PGC-1α  are up-regulated during adaptive 
mitochondrial response of skeletal muscle to exercise training [38, 39] and in cultured 
myotubes in response to increased calcium [40]. PGC-1β  also is a potent co-activator of 
NRF-1. An increase in PGC-1β  expression in transgenic mice promotes, associated 
with an increase of oxidative muscle fibers, a massive increase of mitochondrial 
contend and high levels of mitochondrial respiratory genes transcription [41]. Thus, 
PGC-1α , PGC-1β  and PRC bind NRF-1 in order to trans-activate NRF-1 target genes. 
Serum treatment of quiescent fibroblast induces PRC expression, followed by an 
increase of TFAM, TFB1M and B2 genes, as well as nuclear and mitochondrial 
encoded subunits of respiratory complexes. Functional binding sites for NRF-2 (the 
human homolog of mouse GA- binding protein) have been localized to the promoters of 
numerous genes related to respiratory chain, mainly COX subunits [42, 43], as well as 
to TFAM [44],TFB1 and B2 promoters [37]. It has been speculated that coordinated 
regulation of both NRF-1 and NRF-2 proteins mediated by PGC-1 family members 
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could be a mechanism to ensure the correct expression of essential mitochondrial 
proteins.  
 In the same context, the hormone nuclear receptor ERRα  levels are high in oxidative 
tissues and it modulates the activation of MCAD (medium-chain acyl-coenzyme A 
deshydrogenase) promoter in the β -oxidation pathway [45]. ERRα  has also been 
implicated in PGC-1 induced mitochondrial biogenesis. Mootha and col. (2004),  
through a computational approach to detect cis-regulatory motifs coupled with PGC-
1α -induced genome-wide transcriptional profiles, identified ERRα  and GA-binding 
protein α  (NRF-2 α ) as key transcription factors regulating the OXPHOS pathway. 
Cellular assays confirmed that both proteins were PGC-1α  partners in muscle, 
constituting a double-positive-feedback loop that drives the expression of many 
OXPHOS genes [46]. 
FIGURE 2: Illustration summarizing PGC-1 functions in mammalian muscle cells. PGC-1 co-
activator integrates various physiological cues (red arrow) that are transduced into different signaling 
cascades (yellow arrow) modulating the levels of PGC-1 mRNA and/or protein. In turn, PGC-1 mediated 
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co-activation of several nuclear transcription factors orchestrates specific responses into the muscle cell 
(green arrow). 
In addition to its role in respiratory chain genes and mitochondrial transcription, PGC-
1α  promotes mitochondrial oxidative functions by inducing the expression of genes of 
the mitochondrial fatty acid oxidation and heme biosynthetic pathways. Ligand-
dependent binding PPARα  to PGC-1α  induce the trans-activation of PPARα  target 
genes [47]. Over-expression of PGC-1α  induces MCAD gene expression through its 
interaction with ERRα  [45] and together with NRF-1 and FOXO1 (forkhead, box 
family member) induces δ-aminolevulinate synthase, a critical enzyme in the heme 
biosynthetic pathway [48]. Previously, it has been showed that control of glucose 
oxidation through pyruvate deshydrogenase complex (PDC) could be regulated by 
PGC-1α . PGC-1α  over-expression induces, via ERRα , the transcriptional up-
regulation of PDK-4 (pyruvate deshydrogenase kinase), which inactivates PDC by 
phosphorylation. In addition, PGC-1α  over-expression effects were lost in MEFs 
derived from a ERRα  null mice [49]. Recent studies showed that PDK4 gene 
expression is stimulated by thyroid hormone T(3) demonstrating that following T(3) 
administration there is an increase in the association of PGC-1 α  with the PDK4 
promoter [50]. 
In flies, the majority of the transcription factors that interact with mammalian PCG-1α, 
PGC1β and PRC have been identified. Thus, Drosophila transcription factor erect wing 
(ewg) is the molecular homologue of the NRF-1 gene of vertebrates. ewg has been 
reported as a critical transcription factor during muscle and nervous system 
development. Surprisingly, to date, no ewg function related to mitochondrial biogenesis 
or OXPHOS respiratory chain has been described [51]. Recently, Haussmann and col. 
(2008) have showed that EWG neuronal expression restricts synaptic growth at 
neuromuscular junctions. Using a functional genomics approach in late embryos they 
demonstrated that EWG acts increasing the mRNA levels of genes involved in 
transcriptional and post-transcriptional regulation of gene expression indicating the 
existence of an extensive regulatory network. Then, EWG restricts synaptic growth by 
integrating multiple cellular signaling pathways into an regulatory gene expression 
network [52]. This result may be accounted with the role of NRF-1 as a critical 
regulator in vertebrates. However, genes differentially regulated in ewg mutants were 
not enriched in mitochondrial genes or genes involved in mitochondrial biogenesis. 
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Also, mitochondrial content in synapses was not affected in these mutants. But 
otherwise, in ewg mutants several genes that are differentially regulated are involved in 
energy metabolism through the generation of ATP by inhibiting gluconeogenesis and 
mobilizing lipids stores [52]. Preliminary studies carried out in our lab show that the 
transcription of ewg gene is reduced in null flies. These results are in accordance to the 
muscle phenotype observed in this null mutant (unpublished results). Since, PGC-1α  
null mice have low levels of transcription of NMJ genes in nervous system [53], it is 
worth to speculate that ewg role in NMJ transcriptional regulation in Drosophila could 
be could be mediated by dPGC-1.  
NRF2/GABPα  in Drosophila, named Delg, is required in oogenesis and seems to have 
an equivalent function to its mammalian homologue [54]. This factor is involved in the 
transcriptional regulation of several mitochondrial genes. In addition, is required to 
adjust mitochondrial mass depending on nutrients availability [9]. Previous studies 
showed that dPGC-1 and Delg have a common role in regulating the expression of 
many genes encoding mitochondrial proteins in mid-third instar larvae fat body. 
Moreover dPGC-1 and Delg show synergistic effects over mitochondrial content as 
demonstrated dPGC/Delg double mutant [8].  
Additional Drosophila transcription factors as DREF [DRE (DNA replication-related 
element)-binding factor] regulate the transcription a group of genes involved in 
mitochondrial DNA replication and maintenance as well as several cell proliferation-
related genes [55].  NRGF (nuclear respiratory gene) is a transcription factor that 
regulates the expression of genes with mitochondrial function. Among them, are found 
subunits of the electron transport chain, proteins involved in the oxidative metabolism 
and mitochondrial biogenesis. NRGF binds the NRG response elements which are 
found in more than 50% of the promoters of these genes [56]. Currently, it has been 
speculated that this factor could be putative co-regulators of dPGC-1 mediated 
response. Future approaches will allow the identification of novel co-regulators 
indispensable to determine molecular mechanism of dPGC-1 in Drosophila.  
Physiological pathways implicated in external response to modulate PGC-1 
expression 
In response to external stimuli, physiological effectors pathways mediate changes in the 
transcriptional expression of PGC-1 co-activators. The c-AMP-dependent pathway is 
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one of several that direct the induction of PGC-1α  in a number of tissues. c-AMP is 
induced in response to thermal or fasting signals so that, c-AMP high levels lead to 
activation of CREB family members, through its phosphorylation by protein kinase A 
(PKA). The PGC-1α  promoter has a potent c-AMP response element (CRE) that serves 
as a target for CREB- mediated transcription activation. During energy deprivation 
conditions (reduced ATP) such as starvation, ischemia and chronic metabolic stress, 
AMP-activated protein kinase (AMPK) serves as an energy sensor for whole body 
energy regulation [57]. AMPK is activated by decreases in both the ATP/AMP ratio and 
phosphocreatine content. After activation it increases glucose transport, fatty acid 
oxidation, and mitochondrial biogenesis. In skeletal muscle AMPK directly 
phosphorylates PGC-1α  and increases its expression through a feedback loop [31, 58]. 
Also, skeletal muscle adapts to chronic physical activity through the 
calcium/calmodulin-dependent protein kinase IV (CaMKIV) and calcineurin A (CnA). 
PGC-1α  promoter is regulated by both CaMKIV and CnA activity, and activates PGC-
1α  through the binding of c-AMP response element-binding. Furthermore, the calcium-
signaling pathway may result in a stable induction of PGC-1α , contributing to the 
relatively stable nature of muscle fiber-type determination [59]. 
PGC-1α  also is induced via cGMP-dependent signaling resulted from elevates levels of 
nitric oxide (NO).  Long-term exposure of cells in culture to low concentrations of NO 
induces mitochondrial biogenesis. This process is mediated by cGMP, resulting from 
NO-dependent activation of soluble guanylatecyclase (sGC), and involves increased 
expression of PGC-1α , NRF-1 and Tfam [60]. In addition, studies in mice deficient in 
endothelial NO synthase (eNOS) present reduced mitochondrial biogenesis in tissues 
associated with reduced energy expenditure. NO/cGMP-dependent mitochondrial 
biogenesis yields functionally active mitochondria, in terms of respiratory function and 
metabolic activity [61]. 
Almost nothing is known in Drosophila about how dPGC-1 responds to the different 
external stimuli and how molecular pathways are functionally integrated. Recently 
microarray studies have shown that starvation, produces a subsequent reduction of 
insulin pathway and a decrease of  expression of genes encoding mitochondrial proteins 
[14, 62]. The over-expression of insulin receptor (ISR-1) induces an increase of dPGC-1 
transcription; additionally, transcriptional changes, produced in response to IRS-1 
signaling, is attenuated in hypomorphicdPGC-1 mutant suggesting that dPGC-1 is a 
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mediator of insulin signaling [8]. In other respect, which transcription factors are co-
activated by dPGC-1 to integrate different signal also remain unidentified.  
Tissue protein levels and functions of PGC-1 co-activators 
High levels of PGC-1 co-activators are detected in those tissues with high metabolic 
activity including brown adipose tissue, liver, brain, heart and skeletal muscle.  In 
contrast with other transcriptional co-activators, PGC-1 proteins are highly induced in 
response to developmental stage-specific and physiological cues [6, 17, 18]. PGC-1α  
and PGC-1β  are induced by cold exposure, exercise and fasting in tissue-specific 
patterns [10, 39, 63, 64]. In addition, PGC-1α  is induced in heart at birth and during 
postnatal stages. These stages involve a great mitochondrial biogenesis response as well 
as, in parallel, high energetic requirement [65-67]. In the case of Drosophila dPGC-1 
the situation is comparable. The protein is expressed ubiquitously in flies but high levels 
are detected in the same tissues than in vertebrates, such as skeletal and somatic 
muscles, fat body, lymph gland and central nervous system 
(http://insitu.fruitfly.org/cgi-bin/ex/insitu.pl). Curiously, high levels of mRNA are 
detected also in oocytes, showing that dPGC-1 is supplied like maternal deposit [68].  
Cells with different functions and energetic requirements have different mitochondrial 
content, i.e. number of mitochondria, mtDNA content and/or structures. In addition, 
cells may adapt mitochondrial function in response to cellular or environmental signals 
such as hormones, grow factors, changes in temperature, physiological activity or 
developmental cues. So, the control of mitochondrial biogenesis and function implies 
complex and integrated regulatory networks that depend on the coordinated expression 
of two genomes located in different sub-cellular compartments, the nucleus and the 
mitochondria [69-71]. PGC-1 family members play a critical role in this inter-genomic 
communication reviewed in [7]. 
First of all, in this situation, an important question to answer is if PGC1α  co-activator is 
indispensable for basal mitochondrial physiology. Studies of PGC-1α  loss-of-function 
in mice indicate that this co-activator is dispensable for the basal physiologic processes 
of mitochondria metabolism or fetal development. However, these experiments also 
demonstrated that mice have severely prejudiced their ability to respond to external 
stimuli such as stress, cold exposure or starvation [72, 73]. In this context, therefore, 
PGC-1a seems to be a molecular switch of the metabolic variation to external stimuli. 
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PGC-1a not only plays an essential role in regulating energetic metabolism but also in 
many other processes and events in which mitochondria plays a fundamental role.  
The physiological significance of PGC-1α  and PGC-1β  in mitochondrial energy 
metabolism has been studied by several approaches. Studies of over-expression in 
mammalian culture cell or transgenic mouse, have demonstrated that both PGC-1α  or 
PGC-1β  are able to activate, both, the expression of a number of genes important for 
mitochondrial biogenesis, and respiratory function in adipocytes, cardiac myocytes and 
myogenic cells [11, 30, 65, 74, 75]. These properties are shared by PGC-1β. PGC-1α  
deficiency profoundly perturbs contractile function and leads heart failure [66]. In 
human, the expression of PGC-1 and mitochondrial OXPHOS genes is significantly 
reduced in skeletal muscle of diabetic patients, implicating a potential role for this 
factor in the pathogenesis of insulin resistance [46]. Recently, studies in vivo and in 
vitro demonstrated that PGC-1α  stimulates a broad and powerful program of NMJ 
(neuromuscular junctions)-linked gene expression in skeletal muscle [53]. They 
concluded that PGC-1α to be a key integrator of neuromuscular activity in skeletal 
muscle. Ectopic expression of PGC-1α in muscle results in increased mitochondrial 
number and function as well as an increase in oxidative, fatigue-resistant muscle fibers. 
PGC-1 co-activators mediate muscle external adaptive stimuli (Figure 2). Whole body 
PGC-1α knock-out mice have a very complex phenotype but do not have a marked 
skeletal muscle phenotype. They thus analyzed skeletal muscle-specific PGC-1αknock-
out mice to identify a specific role for PGC-1α in skeletal muscle function. These mice 
exhibit a shift from oxidative type I and IIa toward type IIx and IIb muscle fibers. 
Moreover, skeletal muscle-specific PGC-1αknock-out animals have reduced endurance 
capacity and exhibit fiber damage and elevated markers of inflammation following 
treadmill running. Their data demonstrate a critical role for PGC-1α in maintenance of 
normal fiber type composition and of muscle fiber integrity following exertion. This 
conversion also involves changes in the expression of specific-fiber genes such as 
troponin I (slow) and myoglobin genes. Using culture cells, the same group has shown 
that this regulation is mediated by PGC-1α  co-activation of MEF2 which is a essential 
muscle transcription factors involved in fiber type determination [30, 59].Similarly to 
PGC-1α , transgenic expression of PGC-1β , causes a marked induction of IIX fibers, 
which are oxidative but have "fast-twitch" biophysical properties. PGC-1β  also co-
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activates MEF2 transcription factor to bind to type IIX myosin heavy chain (MHC) 
promoter and activate its expression. PGC-1β  transgenic muscle fibers are rich in 
mitochondria and are highly oxidative, at least in part, due to co-activation by PGC-1 β  
of ERRα  and PPARα . Consequently, these transgenic animals can run for longer and at 
higher workloads than wild-type animals [41]. Moreover, in vivo skeletal muscle 
experiments have demonstrated that PGC-1α  powerfully regulates VEGF (vascular-
endothelial-grow-factor) expression resulting in muscle angiogenesis augmentation. 
PGC-1α  null mice submit to ischemic insult failure to reconstitute blood flow in a 
normal manner to the limb whereas transgenic expression of PGC-1α  in skeletal muscle 
is protective. Instead, PGC-1α  co-activates ERR-α  on conserved binding sites found in 
the promoter VEGF gene. Thus, PGC-1α  and ERR-α  also control a novel angiogenic 
pathway that delivers needed oxygen and substrates [76]. 
 
 
 
 
 
FIGURE 3: The absence of dPGC-1 leads to muscle fiber degeneration, mitochondrial morphology 
and mitochondrial content in null dPGC-1 flies.  Transmission electron microscopic analysis of thorax 
sections from wt and null dPGC-1 flies are shown. A and B panels illustrate longitudinal sections and C 
and D panels show transversal sections.  A and C panels represent wild type flight muscle sections and B 
 16 
and D panels illustrate altered morphology and mitochondria alignment along the fibers in flight muscle 
sections in dPGC -/- flies (arrows and asterisk). (Scale bars=1μm). M, mitochondria; Z, Z axis. 
In the other hand, PGC-1β -deficient mice shows milder stress-induced phenotypes but 
very similar to PGC-1α  null mice [77, 78].  To complete this analysis, double deficient 
PGC-1α  and PGC-1β  null mice were done and the analysis of the phenotype revealed 
that they die shortly after birth as result of heart failure, including abnormal cardiac 
maturation and block in mitochondrial biogenesis. These studies clearly demonstrate 
that both proteins have overlapped targets and therefore, the absence of one of the 
members may be partially compensated by the other factor but the absence of both 
generates a strong phenotype.  
Similar to PGC-1α  deficiency mice, Drosophila dPGC-1 null flies are viable and 
females are sterile. In addition, adult null flies showed locomotor alterations that 
partially unable them to flight (unpublished results). The flight was reduced to 50%, 
indicating an important malfunctioning of flight muscles. Muscle and mitochondria 
morphologies in null flight muscles were examined to determine whether structural 
abnormalities underlay the defects in muscle function. As shown in figure 3, the ultra-
structure of the flight muscles from wild type flies is extremely regular. The myofibrils 
are circular in cross section and exhibit regular sarcomeric units that are aligned in 
parallel between adjacent myofibrils in longitudinal section. Between these myofibrils a 
highly packaged number of electron-dense mitochondria that exhibit the classical 
double membrane structure with cristae visualized as invaginations of inner membrane 
that extend into the matrix are observed together with a small number of nuclei. In 
contrast, flight muscles of mutant null flies exhibit important abnormalities. Thus, most 
of the muscles were severely disrupted and a high percentage of muscle fibers were 
observed wavy, misalignment and degenerated. Myofibril diameters were variable and 
mostly decreased and irregulars.  An important increase of connective tissue was 
visualized between muscle fibers, together with a modestly reduced number and size of 
mitochondria relative to wt muscle control. In addition to being less abundant with 
irregular shapes, these organelles exhibit slightly reduced electron density and, instead 
of recognizable cristae, contain a granular internal structure.  Swollen sarcoplasmic 
reticulum-like structures were frequently observed. This muscle phenotype varies in 
penetrance, some muscles were only moderately disrupted whereas other muscles in the 
same fly are severely affected. Thus, the diminished expression of dPGC-1 protein 
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generates clear muscle abnormalities. These include an increase of connective tissue, 
changes in the mitochondria size and rearrangements in mitochondria and nuclei in 
Drosophila flight muscles. To corroborate these data COX activity assays and NADH 
assays were used to determine mitochondrial mass or OXPHOS activity. Related to fly 
muscle changes, recently, Tiefenbock and others, [8] observed a diminution  of adult 
weight in a hypomorphic allele mutants. Additionally, genes involved in the formation, 
maintaining and function of the fiber, including MEF2 and TnI genes, are also reduced 
in these null mutants (unpublished results). These observations supplies locomotor 
phenotype of dPGC-1 null mutant and also are in agreement with the role of PGC-1 co-
activators family in muscle adaptability function in vertebrates.  
Regarding other functions of PGC-1α  as modulator of other metabolic events, it also 
activates gene regulatory programs involved in hepatic gluconeogenesis [79-81], muscle 
glucose uptake [82, 83], adaptive thermogenesis and heme biosynthesis [48, 84]. Recent 
studies show that PGC-1α  and PGC-1β  control mitochondrial capacity in an additive 
and independent manner in neurons. These evidences demonstrate that activation or 
over-expression of members of the PGC-1 family could be used to compensate for 
neuronal mitochondrial loss [85]. 
The role of the third member of the family, PRC (PGC-1 related co-activator), has been 
investigated by stably silencing PRC expression with two different shRNAs. Complete 
PRC silencing resulted in a severe inhibition of respiratory energy production associated 
with the reduced expression and assembly of respiratory complex. In addition to the 
respiratory defect, PRC silencing was also implicated in the inhibition of cell cycle 
progression. Global changes in gene expression were consistent with both mitochondrial 
and growth phenotypes[86-88]. Recent studies of PRC-loss- function support a role for 
PRC in the integration of pathways directing mitochondrial respiratory function and cell 
growth [89]. 
 
CONCLUDING REMARKS 
 
In this review we have exposed the important role of the PGC-1 co-activator family as 
metabolic sensors. These proteins are central players in the control of organ-specific 
responses to a wide variety of physiological stimuli as well as different kinds of stress. 
We have shown that PGC-1α  is, both in mammals and flies, one of the key regulatory 
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factors in tissues with a high energetic demand. Phenotypic adaptations to different 
signaling pathways, including physical activity, metabolic demands, neuronal 
innervations or ischemia converge on PGC-1 α  regulation through its interaction with 
diverse transcription factors. These interactions increase mitochondrial biogenesis and 
function leading to a higher ATP production through both, OXPHOS metabolism and 
fatty acid β -oxidation. PGC-1α  has a particularly relevant role in muscle development 
and adaptation where this co-factor regulates the expression of fiber specific and NMJ 
post-synaptic genes. On the other hand, in response to ischemia, PGC-1α  regulates 
angiogenesis in muscle, accelerating the recovery of blood flow. In consequence, the 
therapeutic potential of PGC-1α  against diseases associated with deregulated muscle 
function is broad. In fact, PGC-1α  has shown an anti-atrophic effect in different 
experimental systems. 
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